Avacta To Raise GBP48 Million To Accelerate Development Of Therapies Read More
UK TRADING UPDATE SUMMARY: Blencowe And BlueRock Recommence Operations Read More
Avacta Group Reports Widened Loss Amid Higher Operating Expenses Read More
UK TRADING UPDATE SUMMARY: Avacta, Genedrive Progress With Virus Tests Read More
UK Earnings, Trading Statements Calendar - Next 7 Days Read More
UK TRADING UPDATE SUMMARY: BATM Gets EUR29 Million Ventilator Order Read More
Avacta To Co-Develop Test That Can Diagnose Covid-19 In Minutes Read More
Avacta Raises More-Than-Expected GBP3.8 Million In Share Placing Read More
Avacta Announces GBP2 Million Subscription With Two Subscribers Read More
Avacta Inks Cell And Gene Therapy Deal With Joint Venture AffyXell Read More
Avacta Demonstrates Initial Proof Of Concept For Cancer Drug TMAC Read More
Affimer Unit Performance Helps Avacta Revenue Beat Market Forecasts Read More
Avacta Group Hires Vectura Group CFO Fry As Non-Executive Director Read More
Avacta To Establish Gene Therapy Joint Venture With Daewoong Pharma Read More
Avacta Expands Contract With LG Chem After First Programme Completes Read More
Avacta Non-Executive Sam Williams Steps Down After General Meeting Read More
Avacta Plans GBP9 Million Fundraise; Loss Widens On Research Costs Read More
Avacta Teams With ADC Therapeutics To Develop Affimer-Drug Conjugates Read More
LONDON (Alliance News) - Avacta Group PLC on Monday said it has selected a clinical development candidate AVA004 for first-time-in-human clinical trials of its Affimer platform.Affimer an a Read More
